Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

Jack90 Jul. 16 at 5:33 PM

$IBM $ORCL $PFE $BMY opportunity at bottom

0 · Reply

SpudZone Jul. 16 at 4:52 PM

$BMY Dividend name and compounder been holding for years, finally having a great couple weeks. Looking for more action while dividend yield pays out nicely. $JNJ has been sneaky on fire while AI stalls.

0 · Reply

MinimalistKLine Jul. 16 at 3:00 PM

Target $63! Big money loading$BMY dated calls Real-Time Analysis: Pharma giant Bristol Myers Squibb ($BMY) is showing strength, climbing to $59.86. The stock is constructing a solid daily bottom with moving averages beginning to curl upward. Stock Analysis: Yesterday’s options order flow revealed heavy, high-conviction dated call buying targeting $63. Backed by a strong drug pipeline and a reliable 4.2% dividend yield, the downside remains highly protected here. Buyers are stepping in. Do you think BMY easily clears the $63 resistance zone on this run?

1 · Reply

Jack90 Jul. 15 at 6:47 PM

Loading $PFE, $BMY, $JNJ

0 · Reply

SellasgpsCurativeBAT11 Jul. 15 at 3:39 PM

$SLS $MRK $BMY In 2016, a cancer drug maker looked at a huge market and chose, on purpose, to compete for a smaller piece of it. Merck bet built the best-selling drug in the world Keytruda. Its rival chased the whole market, and lost 16% of its value in one morning. We are at that moment with Sellas GPS, big pharmaceutical that makes the moves first wins and leave the others on the sidelines. 👇 ✌️🙏❤️‍🩹

0 · Reply

BioRich Jul. 15 at 1:21 PM

$GUTS Love $GUTS, but sometimes not their biggest fan at how they present things. The data is often much better than how they present it so I took the liberty of cleaning up their slide to remove distraction and it paints the picture we're all hearing and seeing. Hope this helps. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! #FractylForward $XBI $BMY $BIOA $BMEA

1 · Reply

Cedenmo Jul. 14 at 9:54 PM

$BMY damn 1 step forward, 2steps back.,.

1 · Reply

fda_tracker Jul. 14 at 2:53 PM

$BMY New PDUFA Date 2027-05-13 BRISTOL MYERS SQUIBB Link: https://www.businesswire.com/news/home/20260713597234/en/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

LibertarianTreehugger Jul. 14 at 1:46 PM

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb: https://www.fool.com/investing/2026/07/14/donald-trumps-drug-pricing-deals-are-reshaping-big/ $PFE $ABBV $BMY

0 · Reply

Merlintrader Jul. 14 at 12:58 PM

$BBOT BridgeBio Oncology $BBOT Stock Hub 2026 - three KRAS shots on goal (BBO-8520/11818/10203), ~$389M cash into 2028, and the binary 2H26 data that decides it. Field validated by $RVMD, humbled by $BMY Krazati. https://www.merlintrader.com/bridgebio-oncology-bbot-stock-hub/

0 · Reply

Bristol Myers says FDA accepts NDA for mezigdomide

$U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma$

Jul 13, 2026, 6:59 AM EDT - 3 days ago

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

2026-07-10T10:30:55.000Z - 6 days ago

Bristol Myers price target lowered to $66 from $67 at BofA

Jun 25, 2026, 12:26 AM EDT - 21 days ago

Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb

INTC PGR

Jun 18, 2026, 6:59 AM EDT - 4 weeks ago

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Jun 17, 2026, 4:16 PM EDT - 4 weeks ago

Bristol Myers Squibb Announces Dividend

Jun 17, 2026, 12:30 PM EDT - 4 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

Jun 17, 2026, 12:00 PM EDT - 4 weeks ago

3 Stocks to Invest In to Rebalance Your Portfolio

CLX LMT

Jun 11, 2026, 7:03 AM EDT - 5 weeks ago

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial

TAK

Jun 9, 2026, 2:00 PM EDT - 5 weeks ago

Bristol-Myers Squibb Company Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 3:20 AM EDT - 5 weeks ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

LLY MRK PFE RDW UTHR XBI

Jun 8, 2026, 6:59 AM EDT - 5 weeks ago

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

2026-06-03T13:40:17.000Z - 6 weeks ago

Arcus enters clinical trial collaboration, supply agreement with Bristol Myers

RCUS

Jun 3, 2026, 8:00 AM EDT - 6 weeks ago

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

RCUS

2026-06-02T13:36:01.000Z - 6 weeks ago

Bristol Myers, SystImmune announce results from analyses of iza-bren studies

Jun 2, 2026, 8:00 AM EDT - 6 weeks ago

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

2026-06-01T11:16:45.000Z - 6 weeks ago

Bristol Myers: Opdivo in combination with AVD receives expanded EU label

2026-06-01T11:15:21.000Z - 6 weeks ago

Bristol Myers says FDA accepts sNDA for Camzyos

Jun 1, 2026, 6:59 AM EDT - 6 weeks ago

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Jun 1, 2026, 6:55 AM EDT - 6 weeks ago

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

2026-05-31T21:45:07.000Z - 6 weeks ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BNTX

2026-05-29T15:51:38.000Z - 6 weeks ago

C4 Therapeutics jumps after Bristol Myers myeloma data

CCCC

May 29, 2026, 8:02 AM EDT - 6 weeks ago

Bristol Myers drug delays myeloma progression in hard to treat patients

$Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma$

May 29, 2026, 8:00 AM EDT - 6 weeks ago

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

May 27, 2026, 6:59 AM EDT - 7 weeks ago

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 21, 2026, 5:01 PM EDT - 7 weeks ago

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

May 20, 2026, 7:49 AM EDT - 2 months ago

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

May 20, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

May 20, 2026, 6:45 AM EDT - 2 months ago

Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff

May 18, 2026, 9:44 AM EDT - 2 months ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

AZN NVO NVS

May 15, 2026, 11:04 AM EDT - 2 months ago

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

May 14, 2026, 11:40 AM EDT - 2 months ago

Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

TEM

May 12, 2026, 4:01 PM EDT - 2 months ago

Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees

PCRX

May 12, 2026, 2:35 AM EDT - 2 months ago

Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up

May 12, 2026, 12:27 AM EDT - 2 months ago

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

May 12, 2026, 12:19 AM EDT - 2 months ago

China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln

May 8, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

May 6, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Transcript: AGM 2026

May 4, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

ABBV GILD GSK LLY

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Bristol-Myers Squibb Company Quarterly report: Q1 2026

Apr 30, 2026, 7:11 AM EDT - 2 months ago

Bristol Myers Squibb Logs Higher Sales, Profit

Apr 30, 2026, 7:01 AM EDT - 2 months ago

Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales

Apr 30, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

Apr 24, 2026, 8:36 AM EDT - 2 months ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

PFE

Apr 24, 2026, 6:59 AM EDT - 2 months ago

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

RNA

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

ARDX

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Bristol-Myers Squibb Company Proxy statement: Proxy filing

Apr 15, 2026, 7:00 AM EDT - 3 months ago

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

Apr 9, 2026, 7:00 AM EDT - 3 months ago

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Apr 7, 2026, 2:54 PM EDT - 3 months ago

15 stocks to put on your list to buy when the market recovers

ADBE CVS KNSL MS NVDA TGT USB

Apr 3, 2026, 11:08 AM EDT - 3 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 5:34 PM EDT - 3 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 5:33 PM EDT - 3 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN AZN MRK NVO

Apr 2, 2026, 3:29 PM EDT - 3 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV AMGN MRK

Apr 2, 2026, 2:59 PM EDT - 3 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN AZN MRK

Mar 31, 2026, 6:59 AM EDT - 3 months ago

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

Mar 29, 2026, 11:45 AM EDT - 3 months ago

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Mar 28, 2026, 7:00 AM EDT - 3 months ago

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

Jack90 Jul. 16 at 5:33 PM

$IBM $ORCL $PFE $BMY opportunity at bottom

0 · Reply

SpudZone Jul. 16 at 4:52 PM

0 · Reply

MinimalistKLine Jul. 16 at 3:00 PM

1 · Reply

Jack90 Jul. 15 at 6:47 PM

Loading $PFE, $BMY, $JNJ

0 · Reply

SellasgpsCurativeBAT11 Jul. 15 at 3:39 PM

0 · Reply

BioRich Jul. 15 at 1:21 PM

1 · Reply

Cedenmo Jul. 14 at 9:54 PM

$BMY damn 1 step forward, 2steps back.,.

1 · Reply

fda_tracker Jul. 14 at 2:53 PM

0 · Reply

LibertarianTreehugger Jul. 14 at 1:46 PM

0 · Reply

Merlintrader Jul. 14 at 12:58 PM

0 · Reply

JoshAlphaOne Jul. 14 at 9:36 AM

$BMY Entry: 57.90 - 59.34 StopBelow: 56.34 Target: 68.24 Target 2: 77.14 RR 1:3.0

0 · Reply

Rjay1 Jul. 14 at 8:59 AM

$BMY turn up the volume

0 · Reply

JuggernautRaider Jul. 13 at 8:42 PM

$IONS dead money. sell and invest elsewhere. $BMY $INSM $TNXP all buys

0 · Reply

Johnny_Lever Jul. 13 at 5:35 PM

$BMY Let's see if this is for real.

0 · Reply

JuggernautRaider Jul. 13 at 4:36 PM

i'm a sick puppy... i love my $BMY shares, or "pharma bonds" as my friends call them... but I sold a bunch to buy $TNXP $TLSA and $ALLR ... the prices are too cheap, the spreads are too juicy, and The Bonesaw of Biotech is THIRSTY!!! 🍖❤️🍹

1 · Reply

CHItraders Jul. 13 at 11:53 AM

FDA NOD FOR BMY MEZIGDOMIDE $BMY just got FDA acceptance for its New Drug Application on mezigdomide in relapsed or refractory multiple myeloma patients. 🔹 Potential new option for tough-to-treat cases 🔹 Moves Bristol Myers closer to approval 🔹 Another oncology win in a crowded field

0 · Reply

MRTunity Jul. 11 at 2:30 PM

$SLS someone if not $JNJ it will be one of $PFE , $MRK or $BMY who scoops us up very very soon! Regal topline and FA will finally shut the naysayers and trolls up OMCE AND FOR ALL 🚀 🌙

0 · Reply

BioRich Jul. 10 at 10:10 PM

$SGP As folks start to see the potential here, let's not forget the all-star line-up of institutional holdings, led by our favorite RA Capital. Should be interesting to see the new Q2 filings. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $PFE $MRK $BMY

0 · Reply

SGL_FGHI Jul. 10 at 3:18 PM

$TGTX $SNY $BMY $BIIB What’s beautiful about this for a forward-thinking Big Pharma is that TGTX can seamlessly be plugged into their existing neurology sales networks. The winning BP can immediately capture a $4B+ market cap potential without spending years scaling up a brand-new commercial pharmacy infrastructure. For example, because MG is treated by the exact same community neurologists who prescribe MS medications, a Big Pharma acquirer would need zero extra sales infrastructure to cross-sell Briumvi for this indication. The $140.00 per share threshold assumes competitive bidding. This is probably why the buyout will occur SUDDENLY. Personally, I doubt the winning BP will wait until the “de-risked” Phase 3 SUBQ results are reported (expected Q4 2026 / Q1 2027). I expect the winning proposal will be structured with upfront cash and CVR paid out if Briumvi successfully hits its phase 3 endpoint in Myasthenia Gravis OR Schizophrenia.

0 · Reply

SGL_FGHI Jul. 10 at 2:47 PM

$TGTX There are just too many positives for the company's sales -- current and future: Briumvi IV, coming Briumvi SUBQ, and the Myasthenia Gravis (MG) and Schizophrenia (S) indications. This stock seems to only get better. What AI shows today for peak sales: $3.5B-$4.5B Briumvi IV; Briumvi SUBQ $5.25B-$7.0B; MG $750M-$1.2B; S $1.5B-$2.5B for the valuation model. This is a highly desirable multi-tiered autoimmune and neurology franchise. It should be quickly purchased by a Big Pharma with a crumbling patent portfolio, such as $SNY , $BMY , or $BIIB. According to AI, if Big Pharma enters a concurrent bidding war, the acquisition premium can easily breach the $140.00 per share threshold.

1 · Reply

Mike22332233 Jul. 10 at 12:20 PM

$SLS STUNNING PREDICTION JUST OUT ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be * AMAZINGLY GAME-CHANGING * New SoC (and, by the way, STERG just came out in his statement and agreed with all of the above!!) … We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE $ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... A HISTORIC BIDDING WAR !!! AND what do you think of my winning bid BO Price (which I gave in my other post) ??? Like if you agree & FOLLOW ME @Mike22332233 for BO price

1 · Reply

Quantumup Jul. 10 at 11:34 AM

Needham⬆️ $MPLT's PT to $45, from $42,⬆️ML-007-MC aka ML-007PAC PoS to 60 % and reiterated Buy. $ABBV $BMY JNJ OTSKY NBIX LBRX TEVA ATAI RVPH Needham said -- We recently met with management following which we remain optimistic for the upcoming Ph 2b ZEPHYR data readout for ML-007-MC in schizophrenia by mid-August, based on mtg commentary that it continues to see discontinuation and dose step down rates on a blinded basis trend below its expectations. We are increasing the POS from 55% to 60% which takes our PT to $45. In this note, we also highlight what we believe a positive ZEPHYR data could look like and potential readthroughs from ADEPT readout later this year. We expect the momentum in MPLT to continue with the readout of ZEPHYR and ADEPT studies this year.

0 · Reply

Market Cap	116.30B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	10.01
Forward PE	9.38
Profit Margin	14.64%
Debt to Equity Ratio	2.21

Volume	4,811,713
Avg Vol	11,936,723
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	76%
Beta	0.23
Analysts	Sell
Price Target	$62.62